Sources | Names Used |
---|---|
CTRPv2 | doxorubicin:navitoclax (2:1 mol/mol) |
PharmacoGx | doxorubicin:navitoclax (2:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | TIGD3 | CTRPv2 | pan-cancer | AAC | 0.2 | 4e-09 |
mRNA | ARHGAP19-SLIT1 | CTRPv2 | pan-cancer | AAC | 0.23 | 4e-09 |
mRNA | MUM1 | CTRPv2 | pan-cancer | AAC | 0.2 | 4e-09 |
mRNA | MARCKSL1 | CTRPv2 | pan-cancer | AAC | 0.19 | 4e-09 |
mRNA | CTC1 | CTRPv2 | pan-cancer | AAC | 0.22 | 4e-09 |
mRNA | ARHGAP19 | CTRPv2 | pan-cancer | AAC | 0.24 | 5e-09 |
mRNA | NUP133 | CTRPv2 | pan-cancer | AAC | 0.2 | 5e-09 |
mRNA | CIC | CTRPv2 | pan-cancer | AAC | 0.2 | 5e-09 |
mRNA | ABHD17B | CTRPv2 | pan-cancer | AAC | 0.2 | 5e-09 |
mRNA | GMEB1 | CTRPv2 | pan-cancer | AAC | 0.21 | 5e-09 |